Assessing the total costs of blood delivery to hospital oncology and haematology patients

被引:25
作者
Agrawal, Samir [1 ]
Davidson, Neville
Walker, Mel
Gibson, Sian
Lim, Christina
Morgan, Christopher Ll.
Cowell, Warren
机构
[1] Queen Mary Univ London, St Bartholomews Hosp, Dept Haematol Oncol, London E1 4NS, England
[2] Broomfield Hosp, Chelmsford, Essex, England
[3] Roche Prod Ltd, Healthcare Management, Welwyn Garden City, Herts, England
[4] Broomfield Hosp, Helen Rollason Oncol Res Dept, Chelmsford, Essex, England
[5] Cardiff Univ, Dept Med, Cardiff, Wales
关键词
anaemia; blood transfusion; cost; erythropoietin; oncology;
D O I
10.1185/030079906X132532
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Objective: To determine direct costs associated with a blood transfusion session in two hospital settings. Research design and methods: The study was conducted in two United Kingdom hospital sites during April 2004. Transfusion sessions for patients receiving units of red blood cells within either haematology or oncology departments were followed using time and motion techniques to measure the direct costs. Other data were collected from the centres to calculate the cost of disposables, blood wastage and blood bank machines. Results: Total mean staff cost per transfusion of 2 units was pound 37.24 ( pound 9.68 for blood bank and pound 27.56 for ward procedures). The mean cost of disposables was pound 13.25 and the mean cost for blood products was pound 287.56. The mean cost of wastage was pound 11.86 per transfusion. After including other derived costs, such as hospital stay, the mean cost for a transfusion of 2 units of blood was estimated to be pound 546.12. Conclusion: This study estimates the cost of an average blood transfusion of 2 units to be pound 546.12. It should be noted that significant indirect costs, such as those incurred by patients, their carers and societal costs, have not been considered. Against the background of finite blood resources and other factors such as patient quality of life, blood transfusion may not represent the best choice for patient care. Alternative treatments should be considered.
引用
收藏
页码:1903 / 1909
页数:7
相关论文
共 16 条
[1]
Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy [J].
Barrett-Lee, PJ ;
Bailey, NP ;
O'Brien, MER ;
Wager, E .
BRITISH JOURNAL OF CANCER, 2000, 82 (01) :93-97
[2]
Treatment of anaemia in cancer patients: implications for supportive care in the National Health Service Cancer Plan [J].
Bosanquet, N ;
Tolley, K .
CURRENT MEDICAL RESEARCH AND OPINION, 2003, 19 (07) :643-650
[3]
Cavill I, 2002, BRIT MED J, V325, P656
[4]
Epoetin beta - A review of its clinical use in the treatment of anaemia in patients with cancer [J].
Cheer, SM ;
Wagstaff, AJ .
DRUGS, 2004, 64 (03) :323-346
[5]
Cost of outpatient blood transfusion in cancer patients [J].
Crémieux, PY ;
Barrett, B ;
Anderson, K ;
Slavin, MB .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (14) :2755-2761
[6]
Evaluation of the future supply and demand for blood products in the United Kingdom National Health Service [J].
Currie, CJ ;
Patel, TC ;
McEwan, P ;
Dixon, S .
TRANSFUSION MEDICINE, 2004, 14 (01) :19-24
[7]
Chemotherapy-induced anemia in adults: Incidence and treatment [J].
Groopman, JE ;
Itri, LM .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (19) :1616-1634
[8]
The annual cost of blood transfusions in the United Kingdom [J].
Guest, JF ;
Munro, V ;
Cookson, RF .
CLINICAL AND LABORATORY HAEMATOLOGY, 1998, 20 (02) :111-118
[9]
Johansson JE, 2001, SCAND J UROL NEPHROL, V35, P288
[10]
Management options for cancer therapy-related anaemia [J].
Littlewood, TJ .
DRUG SAFETY, 2002, 25 (07) :525-535